C-reactive protein (CRP), a standard marker for inflammation, is an indicator of the severity of recessive dystrophic epidermolysis bullosa…
Articles by Steve Bryson, PhD
The first patient has been dosed in a clinical trial evaluating Aegle Therapeutics‘ AGLE-102, an investigational topical treatment for…
An altered modification of proteins involved in controlling gene activity, called histones, may contribute to how severe the buildup of…
Daclatasvir, an approved antiviral medicine, safely reduced the signs and symptoms of recessive dystrophic epidermolysis bullosa (RDEB) in a…
The enzyme polo-like kinase 1 (PLK1) may be a potential therapeutic target for squamous cell carcinoma (SCC) associated with recessive…
Among a group of people with junctional epidermolysis bullosa (JEB), nearly all genetic mutations associated with the condition were…
Researchers have highlighted the challenges of treating two cases of aggressive squamous cell carcinoma (SCC), a form of skin cancer…
Gene therapy applied to stem cells — ones derived from blister fluid collected from people with recessive dystrophic epidermolysis…
Squamous cell carcinoma (SCC), a form of skin cancer, was the most reported cancer among people with epidermolysis bullosa…
Skin-derived stem cells enhanced wound closure in people with recessive dystrophic epidermolysis bullosa (RDEB), according to clinical trial data.
People with epidermolysis bullosa (EB) have an increased risk of delayed puberty and low bone mineral density (BMD), according…
Genetic defects underlying junctional epidermolysis bullosa (JEB) can also cause kidney-urinary tract symptoms, a case series reports. Researchers recommend…